Sucampo Pharmaceuticals, Inc. Announces Presentation of Results on AMITIZA® (lubiprostone) in Opioid-Induced Constipation at Two Upcoming Scientific Conferences
Published: Oct 11, 2013
BETHESDA, Md., Oct. 11, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") today announced the presentation of three posters evaluating AMITIZA® (lubiprostone) in opioid-induced constipation (OIC). Two posters will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting in San Diego, California on October 13 and 15, 2013, and the third poster will be presented at the American College of Clinical Pharmacy (ACCP) Annual Meeting in Albuquerque, New Mexico on Wednesday, October 16, 2013.
Help employers find you! Check out all the jobs and post your resume.